SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Erasca, Bristol Myers Squibb to Evaluate ERAS-0015 in Clinical Study

The companies will evaluate ERAS-0015 with PRMT5 inhibitor navlimetostat in a clinical study involving MTAP-deleted pancreatic cancer.

BMYERAS

Related stories